CV
CVRX.US CVRx Inc
- Market cap
- USD 17.3M
- P/E
- -
- P/B
- 1.30x
- ROE
- -398.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CVRX.US undervalued?
Graham numberThe Graham number of CVRx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CVRx Inc fundamental analysis
No fundamental analysis for CVRx Inc yet.
CVRx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links …
Full company profileCVRx Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CVRx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6.26M | 6.05M | 13.0M | 22.5M | 39.3M | 51.3M | 56.7M | 59.1M |
| Gross Profit | 4.57M | 4.61M | 9.40M | 17.5M | 33.0M | 43.0M | 48.3M | 51.5M |
| Operating Income | -10.2M | -11.5M | -26.0M | -42.5M | -43.1M | -59.5M | -51.3M | -51.0M |
| EBITDA | -12.8M | -11.5M | -40.6M | -40.7M | -43.1M | -54.9M | -46.7M | -48.2M |
| Net Income | -14.6M | -14.1M | -43.1M | -41.4M | -41.2M | -60.0M | -53.3M | -55.1M |
| EPS | -30 | -36 | -2.08 | -2.02 | -1.99 | -2.65 | -2.04 | -2.02 |
| Balance Sheet | ||||||||
| Total Assets | 29.1M | 64.8M | 153M | 125M | 115M | 133M | 105M | 87.6M |
| Total Liabilities | 308M | 358M | 6.59M | 15.8M | 39.3M | 62.4M | 65.5M | 73.8M |
| Shareholders' Equity | -279M | -293M | 146M | 109M | 75.9M | 71.1M | 39.3M | 13.8M |
| Cash & Short-term Investments | 25.7M | 59.1M | 142M | 106M | 90.6M | 106M | 75.7M | 58.7M |
| Total Debt | 19.0M | 19.3M | - | 7.09M | 30.6M | 50.4M | 50.8M | 59.4M |
| Cash Flow | ||||||||
| Operating Cash Flow | -12.8M | -16.1M | -27.7M | -42.7M | -39.0M | -39.1M | -40.2M | -42.5M |
| Capital Expenditure | 106K | 311K | 1.18M | 685K | 591K | 1.36M | 580K | 443K |
| Free Cash Flow | -12.9M | -16.4M | -28.9M | -43.4M | -39.6M | -40.5M | -40.8M | -43.0M |
| Ratios | ||||||||
| ROE | - | - | -29.5% | -37.9% | -54.2% | -84.4% | -135.6% | -398.8% |
| ROA | -50.3% | -21.8% | -28.2% | -33.2% | -35.8% | -44.9% | -50.9% | -62.9% |
| Net Profit Margin | -233.9% | -233.1% | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% | -93.3% |
| Debt to Equity | - | - | - | 0.06x | 0.40x | 0.71x | 1.29x | 4.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CVRx Inc dividends
CVRx Inc has not paid dividends in the last 7 fiscal years.
Who owns CVRx Inc
- Insiders 10.32%
- Institutions 63.33%
- Public & others 26.35%
- Shares outstanding 28.5M
- Free float 20.2M
Top funds holding CVRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 684K | 2.57% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 363K | 1.36% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 258K | 0.97% | 0.00% | Oct 2026 |
| First Eagle Small Cap Opportunity I | 193K | 0.72% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 158K | 0.59% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 89.3K | 0.34% | +1.39% | Sep 2026 |
| Fidelity Extended Market Index | 64.5K | 0.24% | -31.79% | Sep 2026 |
| iShares Micro-Cap ETF | 46.9K | 0.18% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 35.5K | 0.13% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 35.4K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 34.3K | 0.13% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 32.9K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 27.8K | 0.10% | 0.00% | Sep 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 27.8K | 0.10% | +281.54% | Jul 2026 |
| Nuveen Equity Index R6 | 27.2K | 0.10% | 0.00% | Aug 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 26.9K | 0.10% | -6.50% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 23.0K | 0.09% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 22.1K | 0.08% | 0.00% | Aug 2026 |
Top institutions holding CVRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Johnson & Johnson | 4.02M | 14.13% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 1.95M | 6.86% | -3.54% | Jun 2026 |
| BlackRock Inc | 1.25M | 4.37% | +21.32% | Jun 2026 |
| Royal Bank of Canada | 1.23M | 4.33% | +74.44% | Jun 2026 |
| GSK PLC | 1.01M | 3.54% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 911K | 3.20% | -0.08% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 878K | 3.08% | +53.51% | Jun 2026 |
| Geode Capital Management, LLC | 441K | 1.55% | +3.21% | Jun 2026 |
| Partner Fund Management LP | 370K | 1.30% | 0.00% | Jun 2026 |
| State Street Corp | 366K | 1.29% | +4.51% | Jun 2026 |
| Renaissance Technologies Corp | 230K | 0.81% | +1,091.71% | Jun 2026 |
| UBS Group AG | 224K | 0.79% | +116.00% | Jun 2026 |
| Tudor Investment Corp Et AL | 206K | 0.72% | +4.23% | Jun 2026 |
| The Goldman Sachs Group Inc | 150K | 0.52% | -25.62% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 145K | 0.51% | +4.03% | Jun 2026 |
| Kestra Advisory Services, LLC | 132K | 0.46% | +176.41% | Jun 2026 |
| Two Sigma Investments LLC | 132K | 0.46% | +15.97% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 129K | 0.45% | +0.93% | Jun 2026 |
| Northern Trust Corp | 125K | 0.44% | -16.89% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 106K | 0.37% | +11.67% | Jun 2026 |
CVRx Inc company profile
- Company name
- CVRx Inc
- Ticker
- CVRX.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 223
- Fiscal year end
- December
- Address
- 9201 West Broadway Avenue, Minneapolis, MN, United States, 55445
- Phone
- 763 416 2840
- Website
- barostim.com
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx Inc management
10- Mr. Kevin HykesPresident, CEO & Director · born 1966
- Dr. Philip B. Adamson M.D., M.Sc.Chief Medical Officer · born 1961
- Mr. John LandryChief Financial Officer · born 1973
- Mr. Brent BinkowskiChief Operating Officer · born 1969
- Mr. Matt KleinVice President, Legal & Compliance Officer
- Mr. Paul VerrastroInterim Head of Sales · born 1963
- Mr. Patrick LyonVice President of Marketing
- Mr. Gregory MorrisonChief Human Resources Officer · born 1964
- Mr. Jared OasheimConsultant · born 1983
- Ms. Bonnie Handke M.B.A., R.N.Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics